In HCV genotype 1-infected patients with HIV co-infection, tritherapy [HCV protease inhibitors (PIs) plus peg-interferon and ribavirin] has been shown to have an increased rate of sustained virological response. However, complex drug-to-drug interactions and tolerability issues remain a concern. Methods: Under the auspices of four French...
-
2014 (v1)Journal articleUploaded on: December 4, 2022
-
2020 (v1)Journal article
International audience
Uploaded on: December 3, 2022 -
2017 (v1)Journal article
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) - Boston, MA - 2016-11-11
Uploaded on: February 28, 2023 -
March 19, 2018 (v1)Journal article
Background: Failure to achieve sustained virological response (SVR) with hepatitis C virus (HCV) direct-acting antiviral (DAA)–based regimens is commonly associated with emergence of resistance-associated substitutions (RASs). Retreatment of patients who failed prior DAAs remains challenging. The aim of this prospective and randomized study was...
Uploaded on: February 27, 2023 -
April 2022 (v1)Journal article
International audience
Uploaded on: December 3, 2022 -
2018 (v1)Journal article
BACKGROUND & AIMS: More than 90% of cases of hepatocellular carcinoma (HCC) occur in patients with cirrhosis, of which alcohol is a major cause. The CIRRAL cohort aimed to assess the burden of complications in patients with alcoholic cirrhosis, particularly the occurrence of HCC.METHODS: Patients with biopsy-proven compensated alcoholic...
Uploaded on: December 4, 2022 -
2020 (v1)Journal article
Background & Aims Hepatitis C virus (HCV) genotype (GT) 4 infection is prevalent in sub-Saharan Africa and the Middle East, particularly in Egypt. This study evaluated the safety and efficacy of elbasvir/grazoprevir administered for 8 and 12 weeks in participants with HCV GT4 infection. Methods In this partially randomized, open-label...
Uploaded on: December 3, 2022